Skip to main content Skip to main navigation menu Skip to site footer

Perbedaan Kadar serum Liver-Type Fatty Acid Binding Protein (L-FABP) dan Beta Trace Protein (BTP) Dalam Serum Sebelum dan Saat Cedera Ginjal Akut

  • Mona Yuliari ,
  • Hani Susianti ,
  • Deasy Ayuningtyas Tandio ,

Abstract

Background: The prevalence of Acute Kidney Injury (AKI) varies, ranging from 3% to 20% of hospitalized patients and 25% to 67% of ICU patients, with 5% to 6% of the ICU population requiring renal replacement therapy following AKI. Establishing the diagnosis of AKI with KDIGO criteria using serum creatinine marker. Serum creatinine has a sensitivity of 52.9% and a specificity of 85.7% for AKI. The Sensitivity and specisifity of serum creatinine is not good because it can increase without any real injury or do not change even though acute tubular injury has occurred due to compensation for increased function by the remaining nephrons. L-FABP (Liver type Fatty Acid Binding Protein) and BTP (Beta Trace Protein) serum are newly discovered biomarkers potential for the early diagnosis of acute kidney damage. This study was conducted to determine the change in L-FABP and BTP concentration levels as markers of AKI.

Method: This study is a longitudinal observational study with patients suffering from AKI with serum samples taken before and after an increase in serum creatinine level of ≥0.3 mg/dL in 48 hours. Serum levels of L-FABP and BTP were examined by ELISA method, and serum creatinine by enzymatic colorimetric. Differences between levels before and during AKI were analyzed by the Wilcoxon test.

Results: The number of research subjects was 40 people. There was significant difference between serum creatinine before and during AKI (1.97 (1.36-2.77) mg/dL vs. 3.52 (2.53-4.91). mg/dL, p<0.001). Indeed there were also significant differences in serum L-FABP before and during AKI (3775.48 (1614.11-5086.68) ng/mL vs. 5427.28 (4562.79-5765.14) ng/mL, p<0.001), and serum BTP levels before and during AKI (456.36 (290.35-591.67) mg/L vs. 518.38 (436.37-691.90) mg/L, p<0.001).

Conclusion: Serum levels of L-FABP and BTP increased significantly in the condition of the AKI so that it has the potential to be a marker for the diagnosis of AKI.

 

Latar belakang: Prevalensi cedera ginjal akut (Acute Kidney Injury/AKI) bervariasi, sekitar 3% hingga 20% dari pasien rawat inap dan 25% hingga 67% dari pasien ICU, dengan 5% hingga 6% dari populasi ICU membutuhkan terapi penggantian ginjal setelah terjadi AKI. Penegakan diagnosis AKI dengan kriteria KDIGO menggunakan marker serum kreatinin. Serum kreatinin mempunyai sensitivitas 52,9% dan spesifisitas 85,7% untuk AKI. Sensitivitas dan spesifisitas serum kreatinin tersebut kurang baik karena kadar serum kreatinin dapat meningkat tanpa ada cedera nyata maupun tidak berubah meskipun telah terjadi cedera tubulus akut karena adanya kompensasi peningkatan fungsi oleh nefron yang tersisa. Serum L-FABP (Liver type Fatty Acid Binding Protein) dan BTP (Beta Trace Protein) adalah biomarker yang ditemukan untuk diagnosis dini AKI. Penelitian ini dilakukan untuk mengetahui perubahan kadar serum L-FABP dan BTP sebagai penanda terjadinya AKI.

Metode: Penelitian ini adalah penelitian observasional longitudinal dengan subyek pasien yang menderita AKI dengan sampel serum yang diambil sebelum dan sesudah terjadi peningkatan kadar serum kreatinin ≥0,3 mg/dL dalam 48 jam. Kadar serum L-FABP dan BTP diperiksa dengan metode ELISA, dan serum kreatinin dengan metode enzimatik kolorimetrik. Perbedaan antara kadar sebelum dan saat AKI dianalisis dengan uji Wilcoxon.

Hasil: Jumlah subyek penelitian adalah 40 orang. Terdapat perbedaan bermakna antara kreatinin serum sebelum dan selama AKI (1,97 (1,36-2,77) mg/dL vs 3,52 (2,53-4,91), mg/dL, p<0,001. Teradapat juga perbedaan yang signifikan dalam serum L-FABP sebelum dan selama AKI (3775,48 (1614,11-5086,68) ng/mL vs 5427,28 (4562,79-5765,14) ng/mL, p<0,001), dan kadar BTP serum sebelum dan selama AKI (456,36 (290,35-591,67) mg/L vs. 518,38 (436,37-691,90) mg/L, p<0,001).

Simpulan: Kadar serum L-FABP dan BTP meningkat signifikan pada kondisi AKI sehingga berpotensi menjadi marker untuk diagnosis AKI.

References

  1. Alpern R, Caplan M, Moe O, eds. Seldin and Giebisch’s The Kidney. 5th ed. Elsevier Inc.; 2013. doi:10.1016/B978-0-12-381462-3.00075-6
  2. Levey AS, James MT. Acute Kidney Injury. Ann Intern Med. 2017;167(9):ITC66-ITC80. doi:10.7326/AITC201711070
  3. Dobrek L, Thor P. Novel biomarkers of acute kidney injury and chronic kidney disease. Polish Ann Med. Published online 2016:1-8. doi:10.1016/j.poamed.2016.10.002
  4. Puspitawati I, Jufan AY, Cahyaningrum V, Dewi CT, Chasanah I, Triyono T. Urine neutrophil gelatinase-associated lipocalin (NGAL) as an initial biomarker of acute kidney injury (AKI) in an intensive care unit (ICU) patients: a preliminary study. Bali Med J. 2019;8(2 SE-ORIGINAL ARTICLE):390-393. doi:10.15562/bmj.v8i2.1458
  5. Makris K, Spanou L. Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. Clin Biochem Rev. 2016;37(2):85-98.
  6. Endre H, Pickering JW. Biomarkers and creatinine in AKI: the trough of disillusionment or the slope of enlightenment? Kidney Int. 2016;84(2013):644-647. doi:10.1038/ki.2013.168
  7. Waikar SS, Betensky RA, Emerson SC, Bonventre J V. Imperfect Gold Standards for Kidney Injury Biomarker Evaluation. J Am Soc Nephrol. 2012;23(1):13-21. doi:10.1681/ASN.2010111124
  8. Edelstein CL. Biomarkers in Acute Kidney Injury. Second Edi. Elsevier Inc.; 2017. doi:10.1016/B978-0-12-803014-1/00006-6
  9. White CA, Ghazan-shahi S, Adams MA. β-Trace Protein: A Marker of GFR and Other Biological Pathways. Am J Kidney Dis. 2015;65(1):131-146. doi:10.1053/j.ajkd.2014.06.038
  10. Diagn JMB, El-aarag B, Abdu-allah AM, Abo-alfa MA, El I, El T. Serum Beta-Trace Protein and Cystatin C as Biomarkers for Renal Dysfunction in Patients with Chronic Kidney Disease. J Mol Biomark Diagn. 2018;9(4):9-12. doi:10.4172/2155-9929.1000399
  11. Zdziechowska M, Gluba A, Adam B, Beata RP, Michał F. Serum NGAL, KIM‑1, IL‑18, L‑FABP: New biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. Int Urol Nephrol. 2020;52(11):2135-2143. doi:10.1007/s11255-020-02530-x
  12. Xu Y, Xie Y, Shao X, Ni Z, Mou S. L-FABP: A novel biomarker of kidney disease. Clin Chim Acta. 2015;445:85-90. doi:10.1016/j.cca.2015.03.017
  13. Solichova P, Novackova L, Ochmanova R, Stejskal D. Assessment of serum β-Trace Protein (BTP) measurement in the prediction of glomerular filtration rate. Comparison with serum Cystatin C. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006;150(1):83-84.
  14. Wajda J, Dumnicka P, Sporek M, et al. Does Beta-Trace Protein (BTP) Outperform Cystatin C as a Diagnostic Marker of Acute Kidney Injury Complicating the Early Phase of Acute Pancreatitis? J Clin Med. 2020;9(1):1-14.
  15. Chakraborty D, Akbari A, Knoll GA, et al. Serum BTP concentrations are not affected by hepatic dysfunction. BMC Nephrol. 2018;19:1-6.
  16. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. Kidney Int. 2008;73(9):1008-1016. doi:10.1038/sj.ki.5002729
  17. Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008;(c):465-472. doi:10.1038/sj.ki.5002721
  18. Connolly M, Kinnin M, Mceneaney D, et al. Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography. QJM. 2018;111(2):103-110. doi:10.1093/qjmed/hcx201
  19. Lipiec K, Adamczyk P, Świętochowska E, Ziora K, Szczepańska M. L-FABP and IL-6 as markers of chronic kidney damage in children after hemolytic uremic syndrome. Adv Clin Exp Med. 2018;27(7):955-962. doi:10.17219/acem/70567

How to Cite

Yuliari, M., Susianti, H., & Tandio, D. A. (2022). Perbedaan Kadar serum Liver-Type Fatty Acid Binding Protein (L-FABP) dan Beta Trace Protein (BTP) Dalam Serum Sebelum dan Saat Cedera Ginjal Akut. Intisari Sains Medis, 13(2), 377–380. https://doi.org/10.15562/ism.v13i2.1409

HTML
0

Total
0

Share

Search Panel

Mona Yuliari
Google Scholar
Pubmed
ISM Journal


Hani Susianti
Google Scholar
Pubmed
ISM Journal


Deasy Ayuningtyas Tandio
Google Scholar
Pubmed
ISM Journal